Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU


ABSTRACT: Patients with haematological malignancies developing severe pulmonary complications have a poor outcome, especially after bone-marrow transplantation (BMT). We studied the aetiology, the yield of different diagnostic tools, as well as the outcome and prognostic factors in the corresponding population admitted to our respiratory intensive care unit (RICU).

Overall, 89 patients with haematological malignancies and pulmonary complications treated within a 10 yr period were included.

The underlying malignancies were predominantly acute leukaemia and chronic myeloid leukaemia (66/89, 74%). Fifty-two of 89 (58%) patients were bone marrow recipients. An aetiological diagnosis could be obtained in 61/89 (69%) of cases. The aetiology was infectious in 37/89 (42%) and noninfectious in 24/89 (27%). Blood cultures and cytological examinations of bronchoalveolar lavage fluid were the diagnostic tools with the highest yield (13/43 (30%) and 13/45 (29%) positive results, respectively). Necropsy results were coincident with results obtained during the lifetime in 43% of cases with infectious and 60% with noninfectious aetiologies. Overall mortality was 70/89 (79%), and 47/52 (90%) in transplant recipients. The requirement of mechanical ventilation, BMT, and an interval <90 days of BMT prior to ICU admission were independent adverse prognostic factors.

The outcome in this patient population was uniformly poor. It was worst in bone marrow recipients developing pulmonary complications <90 days after transplantation and requiring mechanical ventilation. Decisions about intensive care unit admission and mechanical ventilation should seriously consider the dismal prognosis of these patients.

The treatment of haematological malignancies is frequently associated with pulmonary complications, including infectious and noninfectious aetiologies [1–4]. The prognosis of these patients worsens significantly when respiratory failure requiring intensive care unit (ICU) treatment and mechanical ventilation occurs [5, 6]. Despite adequate diagnostic evaluation and treatment in an ICU, mortality remains so high that the benefits of the use of mechanical ventilation have been seriously questioned. This is especially true for bone marrow transplant recipients [7–11].

We, therefore, report our experience in the treatment of patients with haematologic malignancies and pulmonary complications admitted to our respiratory intensive care unit (RICU). We studied the aetiology of pulmonary compromise and determined the value of different diagnostic tools as well as the information obtained by necropsy. Moreover, we looked for prognostic factors associated with mortality.

Materials and methods

Patient population

The clinical charts of all patients with haematological malignancies and pulmonary complications admitted to our ICU between January 1, 1984 and December 31, 1993 were retrospectively recorded. Overall, 89 patients were considered adequate for evaluation.

Data collection

In all cases, the following variables were recorded: age, sex, underlying haematological malignancy, presence or absence of bone marrow transplantation (BMT), allogeneic or autologous BMT and interval from BMT to ICU admission. From the variables available at admission, leucocyte count, platelet count, prothrombin, creatinine, arterial oxygen tension (P\textsubscript{a}O\textsubscript{2}), inspiratory oxygen fraction (F\textsubscript{I}O\textsubscript{2}) and the type (alveolar, interstitial, mixed), as well as the distribution of radiographical infiltrates (uni- versus bilateral) were recorded. Chemotherapy and/or radiotherapy received, antimicrobial treatment during hospitalization, the absence or presence of adult respiratory distress syndrome (ARDS; as defined by MURRAY et al. [12]), the requirement of mechanical ventilation, and the duration of mechanical ventilation were retrieved.

The aetiology of pulmonary compromise was classified as definitely infectious, noninfectious or undetermined. An aetiology was considered definite in the case of a
microbiological confirmation of infection by respiratory or nonrespiratory samples and/or necropsy (see Diagnostic criteria). The diagnosis of a noninfectious aetiology was based on 1) the absence of a definite infectious aetiology; 2) evidence for a noninfectious aetiology as determined by clinical criteria and a compatible clinical course; or 3) necropsy results. Episodes that did not meet criteria for infectious or noninfectious aetiologies were classified as undetermined.

The clinical outcome was evaluated in terms of death in the ICU or discharge from ICU. Patients were grouped as survivors versus nonsurvivors, accordingly.

### Microbiological evaluation

Noninvasive as well as invasive bronchoscopic evaluation was performed according to the clinical judgment of the physicians in charge. Microbiological testing was performed as previously described [13]. In short, the respiratory samples were cultured for aerobic and anaerobic bacterial pathogens, mycobacteria, and fungi. In addition, they were evaluated by direct fluorescent antibody (DFA) technique for Legionella spp. Undiluted and serially diluted secretions were plated on blood-sheep agar, Wilkens-Chalgren, chocolate agar as well as Sabouraud's agar. All cultures were incubated at 37°C in aerobic and anaerobic culture and in a CO2-enriched atmosphere. Negative bacterial cultures were discarded after 5 days, and negative fungal cultures after 4 weeks.

Smears obtained by cytocentrifuge preparation were stained with Papanicolaou, May-Grünwald Giemsa, PAS, haematoxylin-eosin, Perls, and Gomori-Grocott, and examined for cytological evidence of viral inclusion bodies, fungal, toxoplasmosis, and Gomori-eosin stain. Negative bacterial cultures were discarded after 5 days, and negative fungal cultures after 4 weeks.

Smears obtained by cytocentrifuge preparation were stained with Papanicolaou, May-Grünwald Giemsa, PAS, haematoxylin-eosin, Perls, and Gomori-Grocott, and examined for cytological evidence of viral inclusion bodies, fungal, and parasitic infections as well as for the detection of siderophages and malignant cells.

### Diagnostic criteria

Potentially pathogenic bacteria yielding $10^6$ colony-forming units (cfu)-mL$^{-1}$ in cultures of tracheobronchial aspirates (TBAS), $10^5$ cfu-mL$^{-1}$ in cultures of the protected specimen brush (PSB) as well as $10^4$ cfu-mL$^{-1}$ in cultures of bronchoalveolar lavage fluid (BALF) were considered as aetiological agents of pulmonary infiltrates. Any growth of facultative pathogenic bacteria such as Streptococcus viridans and Staphylococcus epidermidis was not considered as relevant. The identification of Legionella spp. and mycobacteria was accepted as diagnostic regardless of colony counts. The isolation of Candida spp. and Aspergillus spp. was considered as diagnostic in the presence of a compatible clinical and radiographical pattern. Pneumonia due to cytomegalovirus (CMV) was diagnosed in case of the demonstration of viral inclusion bodies in cytocentrifuge smears. Pneumocystis carinii pneumonia was diagnosed by a positive Gomori-Grocott stain. Pulmonary haemorrhage was detected by an excess of haemosiderin-laden macrophages recovered from BALF [14]. Any growth of bacteria or fungi in blood cultures (ex-cept S. epidermidis in only one blood culture) in the absence of another infectious focus was considered as presumptive aetiology of pulmonary complications (not necessarily pneumonia). Finally, pneumonia due to Candida spp., Aspergillus sp., CMV, and P. carinii was also established by its demonstration in post mortem lung histology.

### Prognostic analysis

In the whole population, the parameters: mechanical ventilation, presence of BMT, and infectious versus noninfectious and undetermined aetiology were tested for an association with death. In both, patients without BMT and in bone marrow recipients, the following variables were tested: age, $P_{O_2}/F_{O_2}$ at admission, leucocyte and platelet count as well as prothrombin time and creatinine at admission, uni- versus bilateral infiltrates in chest radiographs, bacteremia and fungaemia, infectious versus noninfectious and undetermined aetiology, and requirement of mechanical ventilation. In bone-marrow recipients, the parameters: allogeneic versus autologous transplantation, interval from BMT to ICU admission and history of graft-versus-host disease (GVHD) were tested additionally.

### Statistical analysis

Nonparametric means were compared using Student's t-test. Categorical variables were compared using the chi-square test or Fisher's exact test where appropriate. Parameters significantly associated with death in univariate analysis were included in a multivariate analysis using a stepwise forward logistic regression. An $\alpha$-error of $<0.05$ was considered significant in all cases. All p-values reported are two-tailed.

### Results

#### General characteristics of the study population

The underlying malignancies of the 89 patients (52 male, 37 female, mean age 36±15 yrs, range 8–76 yrs) were predominantly acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), and chronic myeloid leukaemia (CML) (table 1). The majority of patients (78/89, 88%) had received chemotherapy with or without radiotherapy recently during the hospital stay. Fifty-two patients (58%) had undergone BMT (43 allogeneic, nine autologous). The conditioning regimen was cyclophosphamide 120 mg·kg$^{-1}$ plus total body irradiation (TBI) with 12 Gy for allogeneic BMT and autologous BMT of acute leukaemia throughout the study period; patients with autologous BMT for lymphoma received only chemotherapy ("BEAC": 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), etoposide, cytarabine, cyclophosphamide). Granulocyte colony stimulating factor (G-CSF) was regularly added since 1991 in patients with autologous BMT from day 7 until a documented neutrophil count $>1 \times 10^9·L^{-1}$ for three days. Twenty-five BMT

#### Table 1. – Underlying malignancies in 89 patients

<table>
<thead>
<tr>
<th>Underlying malignancy</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myeloid leukaemia</td>
<td>28</td>
<td>31.5</td>
</tr>
<tr>
<td>Acute lymphoblastic leukaemia</td>
<td>22</td>
<td>24.7</td>
</tr>
<tr>
<td>Chronic myeloid leukaemia</td>
<td>17</td>
<td>19.1</td>
</tr>
<tr>
<td>Chronic lymphoid leukaemia</td>
<td>3</td>
<td>3.4</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>8</td>
<td>8.9</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>5</td>
<td>5.6</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>3</td>
<td>3.5</td>
</tr>
<tr>
<td>Aplastic anaemia</td>
<td>2</td>
<td>2.2</td>
</tr>
<tr>
<td>Myelodysplastic syndrome</td>
<td>1</td>
<td>1.1</td>
</tr>
<tr>
<td>Total</td>
<td>89</td>
<td>100</td>
</tr>
</tbody>
</table>

---

Author(s): [Author(s) Name]

Date: [Date]

PULMONARY COMPLICATIONS IN HAEMATOLOGICAL MALIGNANCIES 117
recipients (49%) had already experienced GVHD. Bone
marrow recipients were significantly younger than pa-
tients without BMT (29±11 versus 46±15 yrs, p<0.0001).

Patients were admitted to the ICU because of acute res-
piratory failure (n=61, including n=23 with ARDS), sep-
sis syndrome with and without septic shock (n=11), pul-
monary haemorrhage (n=8), heart failure (n=7), and mis-
cellaneous conditions (fat embolism during bone marrow
infusion and iatrogenic pneumothorax, n=1 each). The mean
$P_{a,o_{2}}/F_{l{o_{2}}}$ at RICU admission was 21.7±9.6 kPa (163±72
mmHg). Seventy-six patients (85%) required mechanical
ventilation.

At admission to the ICU, 73 patients (82%) had a leuco-
cyte count <1×10^9 cells·L⁻¹. All patients except one had
abnormalities in chest radiographs. These were unilateral
in 14 (16%) and bilateral in 74 (84%) of cases, and dis-
closed an alveolar consolidation in 57 cases (65%), an
interstitial pattern in 13 (15%), and a mixed pattern in 18
(20%).

The initial empirical antimicrobial treatment was stand-
ardized according to the following principles. Antibacterial
treatment consisted of a combination regimen including a
third-generation cephalosporin plus an aminoglycoside
(preferably amikacin). Alternatives were an ureidopenicill-
in and ciprofloxacin. If *Staphylococcus aureus* was sus-
pected or proven, vancomycin was added. In the case of
nonresponse, antifungal treatment with amphotericin B
was added empirically after the 4th or 5th day. Ganciclo-
vir plus high-dose immunoglobulin (IgG) immunoglobu-
lins were added since 1990 (and later on, fosfomycin as an
alternative) in the case of a suspected or proven CMV
pneumonia. G-CSF was sporadically administered in pa-
tients with evidence of infection and prolonged neutropenia.

**Diagnostic procedures and number of necropsies**

Blood cultures for bacteria and fungi were obtained in
43 and TBAS in 34 patients. Flexible bronchoscopy was
performed in 50 patients. The investigations included cul-
tures of bronchoalveolar lavage fluid BALF in 49 cases,
and cytological examinations of BALF in 44 cases. PSB
was performed in 43 cases.

Overall, microbiological evaluation, including blood cul-
tures and/or BALF, PSB and TBAS, was performed in 64
(72%) patients. One patient had pulmonary tuberculosis.
Thirty-one patients of 70 nonsurvivors (44%) underwent
necropsies.

**Aetiology of pulmonary infiltrates**

A definite aetologic diagnosis of acute respiratory fail-
ure could be obtained by clinical, microbial as well as post
mortem evaluation in 61/89 (69%) of cases. It was infec-
tious in 37 cases (42%). Twenty-four definite noninfec-
tious aetiologies (27%) included diffuse alveolar damage
(DAD) (n=6), pulmonary haemorrhage (n=8, including two
cases associated with DAD and bronchopneumonia, res-
pectively), congestive heart failure (n=7), and organizing
pneumonia as well as severe fat embolism and iatrogenic
pneumothorax in one case each. Twenty eight cases (31%)
remained undetermined, including 15 cases initially pre-
senting with acute respiratory failure, five cases with ARDS
and eight cases with sepsis.

Bacterial pneumonia was the most frequent aetiology
(n=15 plus six cases with mixed bacterial/opportunistic
infections), followed by viral pneumonia (n=7 plus three
mixed infections), fungal pneumonia (n=7 plus four mixed
infections) and *P. carinii* pneumonia (n=1 plus one mixed
infection). However, as regards pathogens, CMV was most
frequently encountered (n=11), followed by *Pseudomonas
aeruginosa* (n=10), and fungal pathogens (*Candida* spp.
n=6, *Aspergillus* spp. n=5). Ten of 37 (27%) episodes ac-
counted for mixed infections. The number of infectious
eaetiologies and pathogenes is listed in table 2. Comparing
patients with and without BMT, the only significant differ-
ence was a higher incidence of CMV in BMT patients (p=
0.007).

**Diagnostic yield of different techniques**

During lifetime, infectious aetiologies were identified in
28 patients. One single additional patient had known pul-
monary tuberculosis. The infectious aetiology was establish-
bled by blood cultures and TBAS as noninvasive diagnostic
tools in 10/28 (36%) cases and by bronchoscopy with PSB
and/or BALF as invasive tools in 14/28 (50%). In the re-
mainning four cases (14%), both procedures contributed to
the diagnosis.

As regards to micro-organisms, blood cultures revealed
a positive result in 13/43 (30%). BALF yielded a positive
result in 15/49 (31%). Of these, culture results were posi-
tive in 2/49 (4%) cases and cytological examinations in
13/45 (29%) cases. PSB was culture-positive in 8/40 (20%)
cases and TBAS were culture-positive in 2/34 (6%) cases.

**Table 2. Infectious aetiologies in 37 patients diagnosed
during lifetime and at necropsy**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Number of cases</th>
<th>Number of pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Bacterial agents</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>11</td>
<td>25</td>
</tr>
<tr>
<td><em>Streptococcus sanguis</em></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><em>Streptococcus mitis</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Streptococcus viridans</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Enterococcus faecalis</em></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><em>Serratia spp.</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Gram-negative enteric bacilli</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td><em>Legionella pneumophila</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Viral agents</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Cytomegalovirus (CMV)</em></td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td><em>Herpes simplex virus</em></td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td><em>Fungal agents</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Candida spp.</em></td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td><em>Aspergillus spp.</em></td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td><em>Pneumocystis carinii</em></td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td><em>Mixed infections</em></td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td><em>L. pneumophila + E. faecalis</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>S. aureus + P. aeruginosa</em></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td><em>S. aureus + P. carinii</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>P. aeruginosa + CMV</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>P. aeruginosa + candida spp.</em></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><em>P. aeruginosa + CMV + Aspergillus spp.</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>P. aeruginosa + CMV + Herpes simplex virus + Aspergillus spp.</em></td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
The diagnostic results of the diverse techniques are listed in table 3. All patients had been pretreated with antimicrobial regimen prior to diagnostic evaluation. Antimicrobial treatment was modified according to diagnostic results in 18/64 cases (28%). Most treatment changes were based on findings in BALF (10 cases) and blood cultures (4 cases).

**Necropsy results**

Eighteen necropsies revealed an infectious aetiology, with 26 pathogens involved. Noninfectious aetiologies were detected in 13 cases. Nine cases with infectious aetiology were associated with DAD (CMV (n=4), P. carinii (n=1), P. aeruginosa (n=1), P. aeruginosa plus CMV plus Herpes simplex plus Aspergillus spp. (n=1), Candida spp. and Aspergillus spp. (n=1 each)). The results are given in detail in table 4.

Necropsy results were coincident with results of diagnostic evaluation *intra vitam* in 6/14 cases (43%) with infectious aetiologies (true positive results) and 6/10 (60%) cases with noninfectious aetiologies (true negative results). In the remaining seven cases, no diagnostic results obtained during the lifetime were available.

Eight infectious aetiologies were exclusively established by necropsy, including two cases with bacterial pneumonia (P. aeruginosa and Enterococcus spp.), one with polymicrobial pneumonia (P. aeruginosa, CMV, and Aspergillus spp.), three cases with pneumonia due to CMV and two cases due to Aspergillus spp.

Of 47 patients with BMT and lethal outcome, necropsy was performed in 22. Pulmonary infection was present in 16. The remaining six disclosed DAD in four cases (three associated with haemorrhage), and pulmonary haemorrhage and bronchopneumonia without pathogen in one case each.

**Outcome and prognostic analysis**

The overall mortality was 70/89 (79%), 23/37 (62%) in nontransplanted patients and 47/52 (90%) in bone marrow recipients (p<0.01). The mortality was 39/43 (91%) in autologous and seven of eight (87%) in autologous transplant recipients (p=0.08). In patients requiring mechanical ventilation, the mortality was 68/76 (90%), as compared to 2/13 (15%) in those not requiring it (p=0.0001).

An infectious aetiology was associated with the highest mortality (32/37, 87%), a noninfectious aetiology with the lowest (15/24, 63%) (p<0.05). An undetermined aetiology had a mortality rate similar to infectious aetiologies (23 of 28, 82%) (p=0.86). The mortality rates for different pathogens were as follows: CMV pneumonia 100% (11 of 11, including three mixed infections); fungal pneumonia 91% (five of six Candida pneumonia, five of five Aspergillus pneumonia, including three mixed infections); bacterial pneumonia 86% (17 of 21, including six mixed bacterial/opportunistic infections); P. aeruginosa pneumonia 100% (10 of 10, including eight mixed bacterial/opportunistic infections), and P. carinii pneumonia 50% (one of two, including one mixed infection).

Of the five BMT recipient survivors, none had any definite infectious aetiology of pulmonary compromise and only two required mechanical ventilation. Of these, one had been transplanted 240 days before and was mechanically ventilated because of cardiogenic oedema; a suspected pneumonia was not proven. The other patient had been transplanted 335 days before and had interstitial pneumonitis. They were ventilated for 9 and 19 days, respectively.

Multivariate analysis of adverse prognostic factors in the whole population including the parameters of mechanical ventilation and presence of BMT revealed that both parameters were independent predictors of death (table 5).

In patients without BMT (n=37), the only parameter significantly associated with death was the requirement of mechanical ventilation. In bone marrow recipients (n=32), the requirement of mechanical ventilation and an interval of <90 days from BMT to ICU admission were significantly associated with death. Both parameters remained independent predictors of death in the multivariate analysis (table 5).
Table 5. – Results of uni- and multivariate analysis of prognostic factors in patients with haematological malignancies and pulmonary complications

<table>
<thead>
<tr>
<th></th>
<th>Relative risk</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total population (n=89)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univariate analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>8.0</td>
<td>4.9–16.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMT</td>
<td>3.9</td>
<td>1.6–9.9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Multivariate analysis</td>
<td>43.7</td>
<td>7.3–260.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>5.2</td>
<td>1.2–22.0</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>BMT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patients without BMT (n=37)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univariate analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>4.2</td>
<td>1.9–8.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMT recipients (n=52)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>18.0</td>
<td>4.1–78.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Interval from BMT to ICU</td>
<td>22.0</td>
<td>2.8–172.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>admission &lt;90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multivariate analysis</td>
<td>25.7</td>
<td>1.0–642.5</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>21.2</td>
<td>1.4–321.3</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Interval from BMT to ICU</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>admission &lt;90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

95% CI: p5% confidence interval; BMT: bone marrow transplantation; ICU: intensive care unit.

Discussion

The main findings of the present study are as follows: 1) The aetiology was infectious in 42%, noninfectious in 27% and remained undetermined in 31% of patients with pulmonary compromise. 2) Blood cultures and cytological examinations of BALF were the diagnostic tools with the highest yield (30% and 29% positive results, respectively). However, necropsy results were coincident with results obtained during lifetime only in 43% of cases with infectious aetiologies and 60% with noninfectious aetiologies. 3) Patients with haematological malignancies and severe pulmonary complications have a high mortality (79%). The requirement of mechanical ventilation, BMT as well as an interval <90 days from BMT to ICU admission were independent adverse prognostic factors.

The principal cause of pulmonary complications in our population was infection. The most frequent infectious aetiology was bacterial pneumonia, with P. aeruginosa representing the leading bacterial pathogen. However, nearly 30% of bacterial pneumonias and 50% of episodes with P. aeruginosa were mixed bacterial/opportunistic infections.

DUNAGAN et al. [15], in a recent report about bronchoscopic evaluation of pulmonary infiltrates in bone marrow recipients also found bacteria as the most common aetiology but Gram-positive pathogens as the most frequent pathogens. Pneumonia due to CMV was the most frequent single aetiologic agent, and as expected occurred signifi-cantly more frequently in transplanted patients as compared with the nontransplanted group. However, the incidence of infection due to CMV has ultimately changed with the practice of providing CMV-negative screened blood to CMV-seronegative marrow recipients, the prophylactic use of hyperim-mune-CMV-Igs, acyclovir or ganciclovir, and pre-emptive therapy [16, 17]. This is also the reason for a clear recent reduction of admissions in our ICU with this type of pulmonary complication. Thus, fungal pneumonia due to Candida spp. and Aspergillus spp. may emerge as leading pathogens in both transplant recipients and nontransplanted patients [18]. Fungal pneumonia due to Candida spp. and Aspergillus spp. was frequently encountered in our study. The mortality rate of infectious complications was generally high (87%). Noninfectious aetiologies were mostly due to pulmonary haemorrhage and heart fail-ure, and the mortality rate in these patients was lower than in patients with infectious aetiologies (63%). A considerable number of episodes remained undetermined. The mortality rate in this latter group of patients was comparable with that infectious aetiologies (82%). This group may include episodes of missed infectious aetiologies, especially bacterial pneumonia, but also idiopathic pneumonia syndrome (IPS) and a variety of inflammatory conditions like DAD, bronchiolitis obliterans with organizing pneumonia (BOOP), bronchiolitis obliterans (BOP), and pulmonary GVHD. The incidence of IPS has been estimated to reach 10–20% [19, 20], and inflammatory conditions as diagnosed by lung histology were found in up to 10% of episodes [19]. As expected, DAD as a uniform result of infectious and noninfectious lung injury was a rather frequent finding on necropsy, with a comparable incidence in patients with and without infection (50 versus 46%).

Bacterial and fungal cultures of respiratory samples retrieved by TBAS, PSB and BALF had a poor diagnostic yield (6, 20 and 4%, respectively). Conversely, cytological examinations of BALF were diagnostic in 29% of the cases investigated. These observations can be explained, on the one hand, by extensive antimicrobial pretreatment impeding growth in culture of respiratory secretions and on the other hand, by the fact that the yield of cytological examinations for respiratory pathogens is less affected by antimicrobial pretreatment. Previous studies investigating bronchoscopic techniques in bone marrow recipients found a yield ranging from 42–66% for bronchoalveolar lavage [3, 21–23] and 31–74% for a combined procedure including transbronchial biopsies [4, 15, 19]. Conflicting results were also reported for the yield of bronchoalveolar lavage in non-transplanted patients with acute leukaemia, with yields ranging from 15–60% [24, 25]. Differences in the severity of pulmonary compromise, the timing of broncho-scopy, guidance of bronchoscopic sampling by computed tomography (CT)-scan of the chest, prophylaxis and antimicrobial pretreatment regimens and microbiological testing may account for the discrepancies in the reported diagnostic yields. In our study, the concordance of diagnostic evaluation during lifetime and necropsy was poor. A significant amount of infectious agents was missed by diagnostic techniques. Three episodes of CMV pneumo-nia were exclusively diagnosed at necropsy, and only one of five cases with Aspergillus pneumonia was diagnosed during lifetime in our study. Whereas new diagnostic tools like shell vial cultures, detection of antigenemia, and CMV deoxyribonucleic acid (DNA) in blood leucocytes by polymerase chain reaction (PCR) have recently significantly improved the diagnostic yield of CMV infection [26], the diagnosis of fungal pneumonia, first of all Aspergillus pneumonia, remains particularly troublesome [24, 25, 27, 28]. Recent approaches in the diagnosis of Aspergillus pneumonia using a CT scan of the chest have shown promising results and may obviate the need for an invasive diagnostic confirmation in a considerable amount of cases [29–31]. Nevertheless, the definite diagnosis of viral as well as fungal pneumonia may require histology, which
PULMONARY COMPLICATIONS IN HAEMATOLOGICAL MALIGNANCIES 121
carries a considerable risk for complications in these severely disabled and mostly thrombocytopenic patients [4, 15, 19]. In any case, our study suggests that for an initial microbiological diagnostic evaluation of these patients blood cultures (with a yield of 30% in our study) together with culture and cytology of bronchoalveolar lavage still represent the most adequate techniques. Notwithstanding, antimicrobial treatment will have to rely largely on empirical approaches.

Our study confirms previous reports demonstrating a high mortality rate in patients with haematological malignancies and severe pulmonary complications [5–10]. Peters et al. [6], in a study including 119 episodes of mechanical ventilation in 116 patients with haematological malignancies, reported an in-hospital mortality of 82%. Schuster and Marron [11] found a mortality of 80% in 77 cases treated in the ICU. We previously reported a mortality of 80% in a series of 30 patients treated in our ICU [5]. The present study found a very similar mortality rate (79%).

Appropriate initial empirical antimicrobial treatment, especially the early introduction of antifungal treatment, is one crucial issue with regard to the outcome of these patients with pulmonary complications [2, 31]. The antifungal treatment approach was consistent during the study period in that broad spectrum antibiotics with anti-Pseudomonas activity were administered initially and antifungal treatment added after the 4th or 5th day in case of nonresponse to antibacterial treatment. As regards CMV, despite major advances in the prevention of pneumonia, the outcome continues to be unfavourable, despite treatment, once pneumonia has developed. Since growth factors have not been shown to improve the outcome of pulmonary complications, its application in sporadic cases is not regarded as a potential confounder in prognostic analysis. The conditioning regimen in bone marrow recipients did not change during the study period. Previous studies have reported an increased mortality from pneumonia in patients with allogeneic as compared with autologous BMT [32]. In our population, with a limited number of patients with autologous BMT, mortality from pulmonary complications was not different to that with allogeneic BMT.

Mortality was independently associated with the requirement of mechanical ventilation and bone-marrow transplantation. An infectious aetiology was associated with a significantly higher mortality than a noninfectious aetiology, but the mortality from an infectious aetiology was not significantly different as compared to the mortality of complications with an undetermined aetiology.

Bone-marrow recipients with pulmonary compromise requiring ICU admission represent a subgroup with a particularly poor prognosis. It has been shown previously that the requirement of mechanical ventilation is an important predictor of mortality in these patients. Mortality rates in these patients ranged between 73 and 96% [7–10, 33]. Moreover, survival rates rapidly dropped after discharge and reached 3% after 6 months [9, 33]. In the present study, 52 transplanted patients were admitted to the ICU, and 47 (90%) died. The mortality rate was independently associated with mechanical ventilation. The mortality rate was 100% in bone marrow recipients requiring mechanical ventilation and concomitant infectious aetiologies. Thus, noninfectious pulmonary complications in bone-marrow recipients may offer more favourable therapeutic prospects, even when mechanical ventilation is required.

The interval from BMT to the development of pulmonary complications has also been related to the outcome. Faber-Langendoen et al. [9] found that bone marrow re-cipients with pulmonary complications developing <90 days after transplantation and being mechanically ventilated had a significantly worse outcome than those occurring after >90 days. This finding could be confirmed in our study. The interval <90 days from BMT to ICU admission was a second independent predictor of death in bone marrow recipients. The high mortality in this period is probably mainly due to opportunistic infections in the presence of severe immunodepletion [16].

The present study is limited to a retrospective survey of a 10 yr series of patients treated at a RICU. Nevertheless, despite considerable progress in the prevention of pulmonary complications after 1990, particularly pneumonia due to CMV, these complications continue to impose diagnostic dilemmas and to be associated with a virtually unaltered poor prognosis. Our study includes a diagnostic evaluation based on a considerable number of necropsies. Moreover, it offers perspectives on populations with different prognostic implications which certainly should be assessed in future prospective trials.

In conclusion, patients with haematological malignancies and severe pulmonary complications present with a variety of aetiologies that can only be incompletely assessed by conventional diagnostic techniques. However, the requirement of mechanical ventilation is the main adverse prognostic factor in both transplanted and nontransplanted patients. Bone-marrow recipients, especially those developing pulmonary complications <90 days after transplantation and requiring mechanical ventilation represent a subgroup with a dismal prognosis. Since intensive care unit treatment with mechanical ventilation bears only a marginal, if any, potential to improve the outcome in this population, emphasis should be placed on the development of better preventive regimen for infectious pulmonary complications [34].

References
7. Crawford SW, Schwartz DA, Petersen FB, Clark JG. Mechanical ventilation after marrow transplantation. Risk


